In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.8 below Zomedica Corp average.

Within Major Pharmaceutical Preparations industry 367 other companies have achieved higher Quick Ratio than Zomedica in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1525 to 2128.

Explain Quick Ratio?
How much Cash & cash equivalents ZOMDF�s has?
What are ZOMDF�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ZOMDF/financial-strength

https://api.csimarket.com/api/v1/companies/ZOMDF/fundamentals

https://api.csimarket.com/api/v1/companies/ZOMDF/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ZOMDF Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	7.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-2.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.8	Subscribe	Subscribe	Subscribe	Subscribe
ZOMDF's Total Ranking	# 2128	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	1.04 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-4.26 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 368
Healthcare Sector	# 662
Overall Market	# 2128

Quick Ratio Statistics
High	Average	Low
140.95	15.1	0.24
(Mar 31 2021)		(Dec 31 2019)

Financial Statements
Zomedica 's Current Liabilities	$ 9 Millions	Visit ZOMDF's Balance sheet
Zomedica 's Cash & cash equivalent	$ 7 Millions	Visit ZOMDF's Balance sheet
Source of ZOMDF's Sales		Visit ZOMDF's Sales by Geography

Cumulative Zomedica 's Quick Ratio

ZOMDF's Quick Ratio for the trailling 12 Months

ZOMDF Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	9.33 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	4.9 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.92	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3963	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	1.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-0.64 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ZOMDF Financial Strength Comparisons >> Go to Compare ZOMDF Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $9.10 millions, cumulative Quick Ratio decreased to 0.92 below the Zomedica Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Zomedica . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2900 to 3963.

Explain Quick Ratio?
How much Cash & cash equivalents ZOMDF�s has?
What are ZOMDF�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 436
Healthcare Sector	# 894
Within the Market	# 3963

trailing twelve months Quick Ratio Statistics
High	Average	Low
72.28	15.77	0.69
(Sep 30 2021)		(Mar 31 2019)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Stoke Therapeutics Inc	2.19	$ 107.271 Millions	$ 48.977 Millions
Quantum Cyber N v	2.17	$ 5.032 Millions	$ 2.319 Millions
Oramed Pharmaceuticals Inc	2.17	$ 29.517 Millions	$ 13.609 Millions
Maravai Lifesciences Holdings Inc	2.14	$ 73.023 Millions	$ 34.160 Millions
Ernexa Therapeutics Inc	2.13	$ 5.575 Millions	$ 2.614 Millions
Madrigal Pharmaceuticals Inc	2.12	$ 962.387 Millions	$ 454.244 Millions
Puma Biotechnology Inc	2.09	$ 108.575 Millions	$ 51.971 Millions
Corcept Therapeutics Inc	2.09	$ 370.703 Millions	$ 177.675 Millions
Biomea Fusion Inc	2.07	$ 26.403 Millions	$ 12.771 Millions
Therapeuticsmd Inc	1.99	$ 10.447 Millions	$ 5.249 Millions
Longeveron Inc	1.96	$ 12.761 Millions	$ 6.527 Millions
Dianthus Therapeutics Inc	1.95	$ 55.686 Millions	$ 28.515 Millions
Xeris Biopharma Holdings Inc	1.95	$ 262.164 Millions	$ 134.479 Millions
Ars Pharmaceuticals Inc	1.95	$ 138.354 Millions	$ 70.995 Millions
Bolt Biotherapeutics Inc	1.93	$ 16.061 Millions	$ 8.315 Millions
Decoy Therapeutics Inc	1.92	$ 8.168 Millions	$ 4.247 Millions
Elite Pharmaceuticals Inc	1.92	$ 34.863 Millions	$ 18.152 Millions
Lite Strategy Inc	1.92	$ 4.281 Millions	$ 2.234 Millions
Mineralys Therapeutics Inc	1.91	$ 101.273 Millions	$ 53.075 Millions
Spero Therapeutics Inc	1.89	$ 107.928 Millions	$ 56.962 Millions
Amarin Corp Plcuk	1.85	$ 323.379 Millions	$ 175.136 Millions
Mustang Bio inc	1.80	$ 14.276 Millions	$ 7.947 Millions
Biovie Inc	1.78	$ 7.733 Millions	$ 4.350 Millions
Alnylam Pharmaceuticals Inc	1.74	$ 3,587.255 Millions	$ 2,063.006 Millions
Mallinckrodt Plc	1.74	$ 1,085.600 Millions	$ 624.900 Millions
Insmed Inc	1.73	$ 1,146.626 Millions	$ 662.181 Millions
Nkarta Inc	1.72	$ 48.354 Millions	$ 28.072 Millions
Cormedix Inc	1.71	$ 355.150 Millions	$ 207.288 Millions
Mannkind Corporation	1.67	$ 181.525 Millions	$ 108.524 Millions
Verastem Inc	1.67	$ 172.801 Millions	$ 103.328 Millions

Date modified: 2026-11-07T13:23:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.